Related Experiment Videos
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments
Abstract:
Single, monolateral injection into rat substantia nigra of manganese chloride produced within two weeks from its administration a loss of dopamine in the striatum ipsilateral to the injected side. The effect was dose-dependent and was not extended to serotoninergic terminals present in this brain area, whose content in serotonin and 5-hydroxyindoleacetic acid was not affected. When L-DOPA + carbidopa or pargyline were given to these animals the decrease of striatal dopamine was more marked. Moreover, rats treated two weeks before with a dose of manganese chloride that produced a 70-80% drop in striatal dopamine concentrations, rotated ipsilaterally to the dopamine-depleted striatum when injected with apomorphine, suggesting that in these animals the stimulatory effects of apomorphine were more relevant in striatum where presynaptic dopaminergic neurons were not affected by manganese chloride. These data indicate that the alterations of dopaminergic postsynaptic receptors may be different in parkinsonian and in manganese-intoxicated patients and that current therapy used for Parkinson's disease could be a hazard in treating manganese poisoning.
Insights
Manganese chloride injection in rats depleted dopamine in the brain, impacting motor control. This suggests Parkinson's disease therapies may be unsafe for manganese poisoning patients.
Area of Science:
- Neuroscience
- Toxicology
- Pharmacology
Background:
- Manganese is an essential trace element but can be neurotoxic at high levels.
- Parkinson's disease is characterized by dopamine deficiency in the striatum.
- Understanding manganese neurotoxicity is crucial for differential diagnosis and treatment.
Purpose of the Study:
- To investigate the effects of manganese chloride on dopaminergic and serotoninergic systems in the rat brain.
- To compare the neurochemical changes induced by manganese with those in Parkinson's disease.
- To evaluate the potential risks of Parkinson's disease therapies in manganese-intoxicated individuals.
Main Methods:
- Unilateral injection of manganese chloride into the rat substantia nigra.
- Dose-dependent assessment of dopamine and serotonin levels in the striatum.
- Administration of L-DOPA + carbidopa or pargyline to assess drug interactions.
- Apomorphine challenge to evaluate behavioral responses (rotation) in manganese-treated rats.
Main Results:
- Manganese chloride caused a dose-dependent loss of dopamine in the ipsilateral striatum within two weeks.
- Serotonin and 5-hydroxyindoleacetic acid levels remained unaffected, indicating selective dopaminergic toxicity.
- L-DOPA + carbidopa or pargyline exacerbated the decrease in striatal dopamine.
- Apomorphine induced ipsilateral rotation in manganese-treated rats, suggesting altered receptor sensitivity.
Conclusions:
- Manganese-induced neurotoxicity selectively affects dopaminergic terminals, differing from Parkinson's disease pathology.
- Current Parkinson's disease treatments could be hazardous in cases of manganese poisoning.
- Further research is needed to differentiate neurochemical alterations and guide therapeutic strategies.